Fig. 4
From: The application of HER2 and CD47 CAR-macrophage in ovarian cancer
The applications of HER2 CAR-M in vivo. A The experimental flow to evaluate the therapeutic effects of HER2 CAR-M on tumor growth in vivo. B 14 days after the establishment of Hu-PBMC model, the proportion of hu-CD45+ cells in mouse PBMC (n = 3). C The percentage of hu-CD45+ cells in PBMC of mice after killing (n = 3). D The inhibitory effect of HER2 CAR-M on tumor growth of HER2hi SKOV3 cell-formed tumors (n = 6). E Flow cytometry analysis of tumor proliferation marker Ki67 (CD11b−Ki67+) in tumor tissues (n = 3). F Flow cytometry analysis of CD8+CD3+ CTL (n = 3). G Flow cytometry results of ratio of M1/M2 in the tumor tissues (n = 3). H Western blot results of PCNA, MHCII, CD163 and CD8 expression in tumors (n = 3). ns not significant; *P < 0.05; **P < 0.01; ***P < 0.001